Taxane-anthracycline combination improves survival of patients with early breast cancer

Hudis, Clifford
March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p42
The article discusses research on the effectiveness of supplementing an anthracycline-based therapy with taxane in increasing the survival rate of high-risk early breast cancer patients. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." Researchers have examined hazard ratios and confidence intervals for disease-free survival and overall survival from trials. The study revealed that taxane administration could have an absolute five-year risk reduction of 3% overall survival and 5% for disease-free survival.


Related Articles

  • Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Kossoff, Ellen; Ngamphaiboon, Nuttapong; Laudico, Thomas; O'Connor, Tracey // Medical Oncology;Dec2011, Vol. 28, p115 

    Ixabepilone 40 mg/m administered on an every 3-week schedule is approved for use in metastatic breast cancer (MBC) as monotherapy, or in combination with capecitabine in anthracycline/taxane resistant tumors. Because the mechanism of action and toxicity profile is similar to the taxanes, it has...

  • Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Du, Xianglin; Xia, Rui; Burau, Keith; Liu, Chih-Chin // Medical Oncology;Dec2011, Vol. 28, p80 

    To determine the risk of cardiotoxicities in association with trastuzumab with/without anthracycline-containing chemotherapy in a large nationwide population-based cohort of patients with breast cancer. We studied 47,806 women with breast cancer ages ≥65 in 1998-2005 from 16 cancer...

  • Small Group of Long-Term Breast Cancer Survivors Who Face Economic Hardships Should Be Targets of Intervention.  // Ascribe Newswire: Health;5/15/2003, p5 

    This article reports on the study of breast cancer survivors, who not only suffer physically from the disease but also face diminished economic well-being, by Thomas N. Chirikos, a member of the cancer control program at the H. Lee Moffitt Cancer Center & Research Institute (HLMCCRI) in Tampa,...

  • Rural-urban disparities in use of post-lumpectomy radiation. Martinez, Steve; Shah, Dhruvil; Tseng, Warren; Canter, Robert; Bold, Richard // Medical Oncology;Dec2012, Vol. 29 Issue 5, p3250 

    We hypothesized that breast cancer (BCa) patients in urban counties would have higher rates of post-lumpectomy radiation therapy (RT) relative to patients in near-metro and rural counties. We used the Surveillance, Epidemiology, and End Results (SEER) database to identify women diagnosed with...

  • Breast cancer: Search for new targets and improvement of existing techniques. Parikh, Bharath R. // Indian Journal of Cancer;Apr-Jun2010, Vol. 47 Issue 2, p95 

    The article discusses various articles published within the issue, including one by V. Wiwanitkit on the ligand-binding sites of the breast cancer molecule BRCA-1 through bioinformatics tools, one by N. E. Avis and colleagues on the studies regarding the quality of life (QoL) and sexual function...

  • IN THIS ISSUE.  // JNCI: Journal of the National Cancer Institute;10/1/2008, Vol. 100 Issue 19, p1337 

    The article discusses several reports published within the issue, including one by Eleni Linos on breast cancer model, and another by Andrea Eisen on the effect of hormone therapy to BRCA1 mutation carriers and childhood cancer survivors' mortality by Ann C. Mertens.

  • Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Romero, A.; Martín, M.; Oliva, B.; de la Torre, J.; Furio, V.; de la Hoya, M.; García-Sáenz, J. A.; Moreno, A.; Román, J. M.; Diaz-Rubio, E.; Caldés, T. // Annals of Oncology;Jul2012, Vol. 23 Issue 7, p1750 

    Background Identification of predicting factors for anthracyclines-based chemotherapy remains a clinical challenge. Glutathione S-transferase (GSTs) enzymes detoxify chemotherapy drugs and their metabolites. Several polymorphisms in GST genes result in reduced or no activity of the enzymes....

  • Ch17CEP duplication predicted anthracycline benefit in early breast cancer.  // Hem/Onc Today;2/25/2010, Vol. 11 Issue 4, p33 

    The article discusses research on the use of chromosome 17 centromere enumeration probe duplication to predict the benefit of anthracycline in early breast cancer patients, by J. M. S Bartett and colleagues, published in the 2010 issue of "Lancet Oncology."

  • Does needle biopsy encourage breast Ca spread?  // Contemporary OB/GYN;Nov2004, Vol. 49 Issue 11, p21 

    The article presents the results of a database study on the effects of receiving fine-needle aspiration or large-gauge needle core biopsy of breast cancer tissue on breast cancer patients, conducted by researchers from California. The researchers found that the increased rate of spread of cancer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics